Balke-Want, Hyatt
Keerthi, Vimal
Gkitsas, Nikolaos
Mancini, Andrew G.
Kurgan, Gavin L.
Fowler, Carley
Xu, Peng
Liu, Xikun
Asano, Kyle
Patel, Sunny
Fisher, Christopher J.
Brown, Annie K.
Tunuguntla, Ramya H.
Patel, Shabnum
Sotillo, Elena
Mackall, Crystal L.
Feldman, Steven A.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
National Institutes of Health
St. Baldrick's Foundation
Parker Institute for Cancer Immunotherapy
Virginia and D.K. Ludwig Fund for Cancer Research
Article History
Received: 20 December 2022
Accepted: 2 June 2023
First Online: 26 June 2023
Declarations
:
: The usage of clinical data was approved by Stanfords internal review board. Animal experiments were approved by Stanford University Laboratory Animal Care (APLAC) protocol.
: All authors agree with the content of the manuscript.
: H.B.W., C.L.M. and S.A.F. are inventors on a Stanford University provisional patent application pending on Homology-Independent Targeted DNA Insertion in human T cells. A.G.M. has been employed by Maxcyte during this study. G.L.K. is an employee of Integrated DNA Technologies, which sells reagents described in this manuscript. G.L.K owns equity in Danaher Corporation, which is the parent company of Integrated DNA Technologies. Shabnum Patel is an employee of Cargo Therapeutics. E.S. consults for Lepton Pharmaceuticals and Galaria; and holds equity in Lyell Immunopharma. C.L.M. holds patents focused on CAR T cells therapies, is a cofounder and holds equity in Lyell Immunopharma, CARGO Therapeutics and Link Cell Therapies, which are developing CAR-based therapies, and consults for Lyell, CARGO, Link, Apricity, Nektar, Immatics, Mammoth and Ensoma.